This disclosure relates to nucleotide and nucleoside therapeutic compounds and uses in treating infectious diseases viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

This disclosure relates to nucleotide and nucleoside therapeutic compounds and uses in treating infectious diseases viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Disclosed herein, inter alia, are compounds, modified nucleotides, compositions, and methods of using the same.

Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing of a nucleic acid.

Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing of a nucleic acid.

The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications.

The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications.

The present invention relates to a nucleoside analog having the structure of the following formula, a method for preparing the nucleoside analog, and an application of the nucleoside analog in nucleic acid sequencing, etc.

##STR00001## wherein L.sub.1, L.sub.2, and L.sub.3 are each independently a covalent bond or a covalently linked group; B is a base or a base derivative; R.sub.1 is —OH or a phosphate group; R.sub.2 is H or a cleavable group; R.sub.3 is a detectable group or a targeting group; R.sub.5 is a polymerase reaction inhibitory group; R.sub.4 is H or —OR.sub.6, wherein R.sub.6 is H or a cleavable group; and C is a cleavable group or a cleavable bond.

The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/CuI. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/CuI. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.